Publications
R.S.Veazey, P.J.Klasse, S.Schader, Q.Hu, T.J.Ketas, M.Lu, P.A.Marx, J.Dufour, R.J.Colonno, R.J.Shattock, M.S.Springer and J.P.Moore. (2005). Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438, 99-102.
R.S.Veazey, M.S.Springer, P.A.Marx, J.Dufour, P.J.Klasse and J.P.Moore. (2005). Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat.Med. 11, 1293-1294.
A.K.Dey, K.B.David, P.J.Klasse and J.P.Moore. (2007). Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360, 199-208.
S.Beddows, M.Franti, A.K.Dey, M.Kirschner, S.P.N Iyer, D.C.Fisch, T.Ketas, E.Yuste, R.C.Desrosiers, P.J.Klasse, P.J.Maddon, W.C.Olson and J.P.Moore. (2007). A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360, 329-340.
T.J.Ketas, S.M.Schader, J.Zurita, E.Teo, V.Polonis, M.Lu, P.J.Klasse and J.P.Moore. (2007). Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364, 431-440.
P.Pugach, T.J.Ketas, E.Michael and J.P.Moore. (2008). Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 377, 401-407.
R.S.Veazey, T.A.Ketas, P.J.Klasse, D.K.Davison, M.Singletary, L.Green, M.L.Greenberg and J.P.Moore. (2008). Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc.Natl.Acad.Sci.USA 105, 10531-10536.
A.K.Dey, K.B.David, M.Lu and J.P.Moore. (2009). Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV 1 envelope glycoproteins. Virology 385, 275-281.
C.G.Anastassopoulou, T.J.Ketas, P.J.Klasse and J.P.Moore. (2009). Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc.Natl.Acad.Sci.USA 106, 5318-5323.
K.Banerjee, S.Andjelic, P.J.Klasse, Y.Kang, R.W.Sanders, E.Michael, R.J.Durso, T.J.Ketas, W.C.Olson and J.P.Moore. (2009). Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389, 108-121.
R.Berro, R.W.Sanders, M.Lu, P.J.Klasse and J.P.Moore. (2009). Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathogens 5, e1000548.
R.S.Veazey, T.J.Ketas, J.Dufour, T.Moroney-Rasmussen, L.C.Green, P.J.Klasse and J.P.Moore. (2010). Protection of rhesus macaques from vaginal infection by vaginally delivered Maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J.Inf.Dis. 202, 739-744.
D.R.Burton, A.J.Hessell, B.F.Keele, P.J.Klasse, T.A.Ketas, B.Moldt, D.C.Dunlop, P.Poignard, L.A.Doyle, L.Cavacini, R.S.Veazey and J.P.Moore. (2011). Limited or no protection by weakly or non-neutralizing antibodies against simian-HIV challenge compared to a strongly neutralizing antibody. Proc.Natl.Acad.Sci. USA (in press).
R.Berro, P.J.Klasse, P.Sachdev, A.Koons, K.A.Nagashima, T.P.Sakmar, T.J.Hope and J.P.Moore. (2011). Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J.Virol. (ePub ahead of print).
P.J.Klasse, R.J.Shattock and J.P.Moore. (2008). Anti-retroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu.Rev.Med. 59, 455-471.
J.P.Moore and D.R.Kuritzkes. (2009). A pièce de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr.Opin. HIV and AIDS 4, 118-124.
P.J.Klasse, R.W.Sanders, A.Cerutti and J.P.Moore. (2011). How can HIV-1 Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res.Human Retroviruses (ePub ahead of print).
